How to access Ebglyss from Saudi Arabia — the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
A Saudi adult or adolescent with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical therapies — or who has not responded adequately to a previous systemic therapy or biologic — may receive a prescription for Ebglyss (lebrikizumab) from their treating dermatologist. Ebglyss is FDA-approved, developed by Eli Lilly, and is a high-affinity monoclonal antibody that binds soluble IL-13 and blocks its assembly of the IL-13Ra1 / IL-4Ra signalling heterodimer. In Saudi Arabia, Ebglyss's local registration status is recent and varies; it may not be broadly available for every patient who clinically qualifies, which is why your dermatologist may be navigating a named-patient import pathway with you.
This guide explains the legal pathway, what your dermatologist needs to provide, typical timelines, and where Reserve Meds fits in.
The clinical situation
Ebglyss is administered subcutaneously. The labelled regimen for moderate-to-severe atopic dermatitis includes an initial loading phase followed by every-two-weeks maintenance through week 16, and a step-down to every-four-weeks maintenance for patients who achieve clear or almost-clear skin at week 16. Eligibility is a clinical decision by your treating dermatologist based on disease severity, prior therapies, and response pattern. Ebglyss's mechanism — blocking soluble IL-13 specifically — is distinct from dupilumab's IL-4Ra blockade and from tralokinumab's different IL-13 binding profile.
Is Ebglyss legally importable into Saudi Arabia?
Yes — through the Saudi Food and Drug Authority (SFDA) named-patient import framework.
The named-patient mechanism allows a Saudi-licensed physician to request import of a medicine not locally registered or not locally available for a specific patient when: (a) the medicine is approved by a recognised reference authority (FDA qualifies), (b) no locally available alternative is clinically equivalent for this patient, (c) the physician takes clinical responsibility, and (d) the importing party documents chain of custody. SFDA reviews each application.
How the pathway works, step by step
- Consultation with your treating dermatologist. Clinical rationale documented, including severity assessment, prior therapies, and Ebglyss as the indicated therapy.
- Import authorisation application. Your dermatologist or the importing pharmacy files the SFDA named-patient documentation including clinical rationale, patient identification (de-identified where possible), product details, and chain-of-custody plan.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner under DSCSA chain-of-custody.
- Cold-chain shipment. Temperature-controlled transport with documented chain of custody.
- Arrival and administration. Subcutaneous administration per your dermatologist's protocol; most patients or caregivers self-inject at home after training.
- Ongoing coordination. Reserve Meds supports re-supply cadence aligned to the loading, every-two-weeks, or every-four-weeks maintenance dosing.
What documentation your physician needs
Your dermatologist will typically need to provide:
- Clinical rationale letter confirming diagnosis, severity, prior therapies, and Ebglyss as the indicated therapy
- Verification of their Saudi medical licence (SCFHS / MOH)
- Patient identifier (anonymised reference where possible)
- Prescription with specified loading and maintenance dose
- Planned administration setting (home-injection or clinic)
Reserve Meds provides a physician documentation kit that bundles the templates SFDA reviewers expect.
Costs and timing
Ebglyss's US cash-pay list price runs in an indicative 2026 range of roughly USD 3,500–4,000 per month at the loading and every-two-weeks maintenance phases, with the every-four-weeks schedule reducing monthly cost for eligible step-down responders. Shipment, cold-chain logistics, and concierge coordination add incremental cost; Reserve Meds issues a transparent quote at the start of intake.
Indicative timeline — not guaranteed — for the first shipment after cohort intake opens is approximately 10–21 days from the moment a complete application is submitted to SFDA. Re-supply is generally faster once the pathway is established.
Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.
A culturally-aware note: atopic dermatitis in Saudi adults and adolescents often has a significant quality-of-life burden during pilgrimage, fasting, and community events; your dermatologist and the Reserve Meds concierge case lead will work around clinic scheduling and travel to minimise disruption.
Reserve Meds's role
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Ebglyss specifically, we provide:
- Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Regulatory documentation package for your physician and for SFDA review.
- Logistics. Cold-chain and temperature-monitored shipment coordination.
- Concierge case lead. A named point of contact throughout the coordination.
What we do not do: We are not the prescriber. We do not practice medicine. We are not the dispensing pharmacy. All clinical decisions remain with your treating dermatologist. We are in pre-launch and operate on a waitlist basis.
Frequently asked
Is this legal? Yes, when executed through the SFDA named-patient framework. See our trust and compliance page.
How does Ebglyss compare with dupilumab and tralokinumab? All three work in the type-2 inflammation axis; Ebglyss and tralokinumab are IL-13-specific (with different binding profiles), and dupilumab blocks the IL-4 receptor alpha affecting both IL-4 and IL-13 signalling. Your dermatologist decides which option fits your history.
Can an adolescent receive Ebglyss? Ebglyss is labelled down to the adolescent age bands in the FDA label. Your dermatologist determines suitability.
Can I self-inject at home? After training by your clinical team, most patients or caregivers self-inject at home using the pre-filled presentation.
What about side effects? Common effects include conjunctivitis, injection-site reactions, and herpes zoster in trial populations; your dermatologist manages monitoring and any adverse events.
Will MoH or insurance cover any of this? Cash-pay is the default for named-patient imports. Some Saudi private insurers reimburse on case-by-case approval; we supply documentation for submission.
Next step — join the first-cohort waitlist
Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Ebglyss coordination.
Add me to the Ebglyss waitlistComposite case examples. Reserve Meds is in pre-launch. This content is for general information and does not constitute medical advice.
Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.